GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (NAS:SGMT) » Definitions » Shiller PE Ratio

Sagimet Biosciences (Sagimet Biosciences) Shiller PE Ratio : (As of Jun. 06, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences Shiller PE Ratio?

Sagimet Biosciences does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sagimet Biosciences Shiller PE Ratio Historical Data

The historical data trend for Sagimet Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences Shiller PE Ratio Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
- - - - -

Sagimet Biosciences Quarterly Data
Dec19 Mar20 Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sagimet Biosciences's Shiller PE Ratio

For the Biotechnology subindustry, Sagimet Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sagimet Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's Shiller PE Ratio falls into.



Sagimet Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Sagimet Biosciences does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.


Sagimet Biosciences  (NAS:SGMT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Sagimet Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sagimet Biosciences (Sagimet Biosciences) Business Description

Traded in Other Exchanges
Address
155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Executives
David Happel director, officer: President & CEO 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Beth C Seidenberg director
Nea 13 Gp, Ltd 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Elizabeth Rozek officer: General Counsel and CCO SAGIMET BIOSCIENCES INC., 155 BOVET ROAD, SUITE 303, SAN MATEO CA 94402
George Kemble director SAGIMET BIOSCIENCES INC., 155 BOVET RD., STE. 303, SAN MATEO CA 94402
Jinzi Jason Wu director SAGIMET BIOSCIENCES INC., 155 BOVET RD., SUITE 303, SAN MATEO CA 94402
Dennis Hom officer: Chief Financial Officer C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Kpcb Pbd Associates, Llc 10 percent owner C/O KLEINER PERKINS CAUFIELD & BYERS, 2750 SAND HILL ROAD, MENLO PARK CA 94025
Kpcb Pandemic & Bio Defense Fund Llc 10 percent owner 2750 SAND HILL RD, MENLO PARK CA 94025
Eduardo Bruno Martins director 350 CAMBRIDGE AVE, SUITE 350, PALO ALTO CA 94306
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Elizabeth A Grammer director 78TH FOURTH AVENUE, WALTHAM MA 02451
Anthony M Rimac officer: Chief Operating Officer C/O ADAMAS PHARMACEUTICALS, INC., 2200 POWELL ST, STE 220, EMERYVILLE CA 94608
Patrick J Kerins 10 percent owner